Especially for triple-negative breast cancers, defined by the lack of both estrogen and progesterone receptors, as well as a lack of overexpression/amplification of the HER2-neu gene, the therapeutic options today are very limited. The gene discussed is PGR; the disease is triple-negative breast carcinoma.